Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Poolbeg Pharma Ltd. (GB:POLB)
LSE:POLB
RESEARCH TOOLSreports
Poolbeg Pharma Ltd. (POLB) Share Price & Analysis
7 Followers
POLB Stock Chart & Stats
Day’s Range0p - 0p
52-Week Range6.38p - 15.77p
Previous Close12.3p
Volume1.64M
Average Volume (3M)2.03M
Market Cap
N/A
Enterprise ValueN/A
Total Cash (Recent Filing)£16.19M
Total Debt (Recent Filing)£0.00
Price to Earnings (P/E)-16.6
Beta2.32
Next Earnings
Sep 03, 2024EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares OutstandingN/A
10 Day Avg. VolumeN/A
30 Day Avg. Volume2,030,001
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Poolbeg Pharma Ltd. News
PremiumCompany Announcements
Poolbeg Pharma Announces 2023 Annual ReportPremiumCompany Announcements
Poolbeg Pharma Secures Key US Patent
PremiumCompany Announcements
Poolbeg Pharma Eyes Significant Market with POLB 001
PremiumCompany Announcements
Poolbeg Pharma Eyes Novel Behçet’s Disease Treatment
PremiumCompany Announcements
Poolbeg Pharma Welcomes New Joint Broker
PremiumCompany Announcements
Poolbeg Pharma Reports Major Shareholder ChangeOptions Prices
Currently, No data available
---
Ownership Overview
7.62% Insiders
0.00% Mutual Funds
0.00% Other Institutional Investors
92.38% Public Companies and
Individual Investors
POLB FAQ
What was Poolbeg Pharma Ltd.’s price range in the past 12 months?
Poolbeg Pharma Ltd. lowest share price was 6.38p and its highest was 15.77p in the past 12 months.
What is Poolbeg Pharma Ltd.’s market cap?
Currently, no data Available
When is Poolbeg Pharma Ltd.’s upcoming earnings report date?
Poolbeg Pharma Ltd.’s upcoming earnings report date is Sep 03, 2024 which is in 105 days.
How were Poolbeg Pharma Ltd.’s earnings last quarter?
Poolbeg Pharma Ltd. released its earnings results on Apr 30, 2024. The company reported -0.004p earnings per share for the quarter, missing the consensus estimate of N/A by -0.004p.
Is Poolbeg Pharma Ltd. overvalued?
According to Wall Street analysts Poolbeg Pharma Ltd.’s price is currently Overvalued.
Does Poolbeg Pharma Ltd. pay dividends?
Poolbeg Pharma Ltd. does not currently pay dividends.
What is Poolbeg Pharma Ltd.’s EPS estimate?
Poolbeg Pharma Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Poolbeg Pharma Ltd. have?
Poolbeg Pharma Ltd. has 500,000,000 shares outstanding.
What happened to Poolbeg Pharma Ltd.’s price movement after its last earnings report?
Poolbeg Pharma Ltd. reported an EPS of -0.004p in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 7.589%.
Which hedge fund is a major shareholder of Poolbeg Pharma Ltd.?
Currently, no hedge funds are holding shares in GB:POLB
---
Poolbeg Pharma Ltd. Stock Smart Score
Not Ranked
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
GB:POLB Sentiment 100%
Sector Average 70%
Sector Average 70%
Insider Transactions
Bought Shares
Worth £16.7K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
68.49%
12-Months-Change
Fundamentals
Return on Equity
-24.00%
Trailing 12-Months
Asset Growth
-20.02%
Trailing 12-Months
Company Description
Poolbeg Pharma Ltd.
Poolbeg Pharma PLC is a clinical-stage infectious disease pharmaceutical company, with a novel capital-light clinical model which enables us to develop multiple products faster and more cost-effectively than the traditional biotech model. The company aspires to become a one-stop shop for Big Pharma seeking mid-stage products to license or acquire.
---
Technical Analysis
---